Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 45

1.

Risk of cancer after assisted reproduction: a review of the available evidences and guidance to fertility counselors.

Del Pup L, Peccatori FA, Levi-Setti PE, Codacci-Pisanelli G, Patrizio P.

Eur Rev Med Pharmacol Sci. 2018 Nov;22(22):8042-8059. doi: 10.26355/eurrev_201811_16434.

PMID:
30536354
2.

Oxygen-ozone therapy as support and palliative therapy in 50 cancer patients with fatigue - A short report.

Tirelli U, Cirrito C, Pavanello M, Del Pup L, Lleshi A, Berretta M.

Eur Rev Med Pharmacol Sci. 2018 Nov;22(22):8030-8033. doi: 10.26355/eurrev_201811_16432.

PMID:
30536352
3.

Biology, staging, and treatment of breast cancer during pregnancy: reassessing the evidences.

Peccatori FA, Lambertini M, Scarfone G, Del Pup L, Codacci-Pisanelli G.

Cancer Biol Med. 2018 Feb;15(1):6-13. doi: 10.20892/j.issn.2095-3941.2017.0146.

4.

Is ovulation induction with letrozole in breast cancer patients still safe even if it could increase progesterone levels?

Del Pup L, Peccatori FA.

Eur Rev Med Pharmacol Sci. 2018 Jan;22(1):246-249. doi: 10.26355/eurrev_201801_14125.

5.

Cancer Targeted Therapy Strategy: The Pathologist's Perspectives.

Alessandrini L, Perin T, Kadare S, Del Pup L, Memeo L, Steffan A, Colarossi L, Berretta M, De Paoli P, Canzonieri V.

Curr Cancer Drug Targets. 2018;18(5):410-420. doi: 10.2174/1568009618666171129145703.

PMID:
29189158
6.

Coffee Decreases the Risk of Endometrial Cancer: A Dose-Response Meta-Analysis of Prospective Cohort Studies.

Lafranconi A, Micek A, Galvano F, Rossetti S, Del Pup L, Berretta M, Facchini G.

Nutrients. 2017 Nov 9;9(11). pii: E1223. doi: 10.3390/nu9111223. Review.

7.

Mechanisms of chemotherapy-induced ovarian damage in breast cancer patients.

Codacci-Pisanelli G, Del Pup L, Del Grande M, Peccatori FA.

Crit Rev Oncol Hematol. 2017 May;113:90-96. doi: 10.1016/j.critrevonc.2017.03.009. Epub 2017 Mar 16. Review.

PMID:
28427528
8.

Use of Complementary and Alternative Medicine (CAM) in cancer patients: An Italian multicenter survey.

Berretta M, Della Pepa C, Tralongo P, Fulvi A, Martellotta F, Lleshi A, Nasti G, Fisichella R, Romano C, De Divitiis C, Taibi R, Fiorica F, Di Francia R, Di Mari A, Del Pup L, Crispo A, De Paoli P, Santorelli A, Quagliariello V, Iaffaioli RV, Tirelli U, Facchini G.

Oncotarget. 2017 Apr 11;8(15):24401-24414. doi: 10.18632/oncotarget.14224.

9.

Letter to the Editor - DTC chemotherapy regimen is associated with higher incidence of premature ovarian failure in women of reproductive age with breast cancer.

Del Pup L, Codacci Pisanelli G, Schettini S, Guido M, Peccatori FA.

Eur Rev Med Pharmacol Sci. 2016 Oct;20(19):3955-3956. No abstract available.

10.

Ospemifene: a safe treatment of vaginal atrophy.

Del Pup L.

Eur Rev Med Pharmacol Sci. 2016 Sep;20(18):3934-3944. Review.

11.

Gonadal agenesis with hypoplastic paramesonephric ducts (PMNDs) derivatives in dizygotic twins.

Miolo G, Del Pup L, Ash A, Manno M, Pivetta B, Tessitori G, Corona G.

Gynecol Endocrinol. 2016 Oct;32(10):792-795. Epub 2016 Jul 5.

PMID:
27379817
12.

Carcinogenetic mechanisms of endocrine disruptors in female cancers (Review).

Del Pup L, Mantovani A, Cavaliere C, Facchini G, Luce A, Sperlongano P, Caraglia M, Berretta M.

Oncol Rep. 2016 Aug;36(2):603-12. doi: 10.3892/or.2016.4886. Epub 2016 Jun 21. Review.

13.

Ovarian transposition in young women and fertility sparing.

Del Pup L, Salvagno F, Borini A, Trovò M, Peccatori FA.

Eur Rev Med Pharmacol Sci. 2016;20(2):197-8. No abstract available.

14.

HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.

Romagnolo C, Leon AE, Fabricio ASC, Taborelli M, Polesel J, Del Pup L, Steffan A, Cervo S, Ravaggi A, Zanotti L, Bandiera E, Odicino FE, Scattolo N, Squarcina E, Papadakis C, Maggino T, Gion M.

Gynecol Oncol. 2016 May;141(2):303-311. doi: 10.1016/j.ygyno.2016.01.016. Epub 2016 Jan 19.

PMID:
26801941
15.

Rational selection of predictive pharmacogenomics test for the Fluoropyrimidine/Oxaliplatin based therapy.

Di Francia R, De Lucia L, Di Paolo M, Di Martino S, Del Pup L, De Monaco A, Lleshi A, Berretta M.

Eur Rev Med Pharmacol Sci. 2015 Nov;19(22):4443-54. Review.

16.

Special issues in fertility preservation for gynecologic malignancies.

Tomao F, Peccatori F, Del Pup L, Franchi D, Zanagnolo V, Panici PB, Colombo N.

Crit Rev Oncol Hematol. 2016 Jan;97:206-19. doi: 10.1016/j.critrevonc.2015.08.024. Epub 2015 Sep 8. Review.

PMID:
26358422
17.

Endocrine disruptors and female cancer: Informing the patients (Review).

Del Pup L, Mantovani A, Luce A, Cavaliere C, Facchini G, Di Francia R, Caraglia M, Berretta M.

Oncol Rep. 2015 Jul;34(1):3-11. doi: 10.3892/or.2015.3997. Epub 2015 May 20. Review.

PMID:
25998096
18.

Prognostic significance of circulating and endothelial progenitor cell markers in type 2 diabetic foot.

Sambataro M, Seganfreddo E, Canal F, Furlan A, Del Pup L, Niero M, Paccagnella A, Gherlinzoni F, Dei Tos AP.

Int J Vasc Med. 2014;2014:589412. doi: 10.1155/2014/589412. Epub 2014 Feb 3.

19.

Nomegestrol acetate/estradiol hormonal oral contraceptive and breast cancer risk.

Del Pup L, Berretta M, Di Francia R, Cavaliere C, Di Napoli M, Facchini G, Fiorica F, Mileto M, Schindler AE.

Anticancer Drugs. 2014 Aug;25(7):745-50. doi: 10.1097/CAD.0000000000000050. Review.

PMID:
24346139
20.

Is effective and safe a radiochemotherapy approach in elderly cancer patients? A review.

Fiorica F, Zanghì A, Pascale G, Nuta O, Del Pup L, Stefanelli A, Cartei F.

Anticancer Agents Med Chem. 2013 Nov;13(9):1430-7. Review.

PMID:
24102273

Supplemental Content

Loading ...
Support Center